Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107796 · ClinicalTrials.gov registry record · Phase 3
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
A Phase 3 study of Narcolepsy, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT00107796: Completed Phase 3 study of Narcolepsy, sponsored by Cephalon.
NCT00107796 is a Phase 3 study of Narcolepsy that has completed, run by Cephalon. The registered enrollment target is 140 participants, below the 369-participant average among 12 other Narcolepsy trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00107796, a Phase 3 study of Narcolepsy, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objectives: The primary objectives of the study are to determine the effectiveness of PROVIGIL treatment, compared to placebo treatment, in children and adolescents with excessive sleepiness (ES) associated with narcolepsy, as assessed by: * mean sleep latency from the Multiple Sleep Latency Test (MSLT) (average of 4 naps performed at 0900, 1100, 1300, and 1500) at the last post-baseline observation (week 6 or early termination) * the Clinical Global Impression of Change (CGI-C) ratings for ES, at the last post-baseline observation (week 6 or early termination).
Conditions Studied
Interventions
- DRUG Modafinil
Study Locations (20)
California
- Julie Thompson-Dobkin, D.O. - Huntington Beach
- Mark Buchfuhrer, M.D. - Long Beach
- Yury Furman, M.D. - Los Angeles
- Stuart Menn, M.D. - Palm Springs
- Richard Shubin, M.D. - Pasadena
- Lawrence Sher, M.D. - Rolling Hills Estates
- Milton K. Erman, M.D. - San Diego
- Stephen Brooks, M.D. - San Francisco
- Paul Haberman, M.D. - Santa Monica
- Jed Black, M.D. - Stanford
Arizona
- Barbara Harris, Ph.D. - Phoenix
- Derek Loewy, Ph.D. - Tucson
- Stuart Quan, M.D. - Tucson
Arkansas
- Joseph McCarty, M.D. - Fort Smith
- John L. Carroll, M.D. - Little Rock
- Samuel Boellner, M.D. - Little Rock
Alabama
- Robert Doekel, Jr., M.D. - Birmingham
- Chris M. Makris, M.D. - Birmingham
Florida
- Amerigo Padilla, M.D. - Miami
- Martin A. Cohn, M.D. - Naples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00107796 record still lists
NCT00107796 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 369-participant average among 12 other Narcolepsy trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Narcolepsy appearing as the primary indexed condition, and to 1 intervention - of which Modafinil is the first listed.
NCT00107796 names 20 study sites across 5 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00107796 about?
NCT00107796 is a clinical study titled "Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy". Primary Objectives: The primary objectives of the study are to determine the effectiveness of PROVIGIL treatment, compared to placebo treatment, in children and adolescents with excessive sleepiness (ES) associated with narcolepsy, as assessed by: * mean sleep latency from the Multiple Sleep Latenc...
What is the current status of trial NCT00107796?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2004-10. Estimated completion is 2005-09.
What conditions does trial NCT00107796 study?
This clinical trial studies the following conditions: Narcolepsy.
What interventions are being tested in trial NCT00107796?
The interventions under investigation include: Modafinil (DRUG).
Who is sponsoring clinical trial NCT00107796?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107796 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Narcolepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00107796's enrollment target sits among peer trials
140 7th of 12 higher than 6 of 12 other Narcolepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Narcolepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
COMPLETED · Phase 3
-
SUNOSI® (Solriamfetol) Pregnancy Registry
RECRUITING
-
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
RECRUITING · Phase 1
-
Child and Adolescent Registry for Participants With Narcolepsy
RECRUITING
-
WAKIX® (Pitolisant) Pregnancy Registry
RECRUITING
-
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia